Daclatone 60 Tablet contains Daclatasvir 60 mg, a potent antiviral medication used for the treatment of chronic Hepatitis C virus (HCV) infection. It works by inhibiting the NS5A protein, which is essential for viral replication, thereby reducing the viral load in the body and preventing further liver damage. Daclatasvir is often used in combination with Sofosbuvir or other antivirals for optimal therapeutic outcomes.
It helps in the antiviral therapy segment, offering targeted treatment for Hepatitis C patients. By interfering with viral RNA replication and assembly, Daclatone 60 significantly improves liver health and recovery chances. Its oral formulation ensures convenience, adherence, and effectiveness for long-term therapy.
From a B2B and PCD franchise perspective, Daclatone 60 Tablet represents a high-value specialty medicine with strong hospital and specialty clinic demand. The growing awareness and screening for Hepatitis C across India have increased the requirement for advanced antiviral therapies like Daclatasvir. Partnering for distribution or marketing of Daclatone 60 ensures consistent prescription flow and a competitive market position.
Manufactured under WHO-GMP-certified facilities, Daclatone 60 offers assured purity, stability, and efficacy. Ideal for inclusion in antiviral, liver care, and specialty medicine portfolios, it provides strong growth potential and contributes to improving patient outcomes in chronic Hepatitis C management.